WO2009137525A1 - High refractive index ophthalmic device materials - Google Patents

High refractive index ophthalmic device materials Download PDF

Info

Publication number
WO2009137525A1
WO2009137525A1 PCT/US2009/042903 US2009042903W WO2009137525A1 WO 2009137525 A1 WO2009137525 A1 WO 2009137525A1 US 2009042903 W US2009042903 W US 2009042903W WO 2009137525 A1 WO2009137525 A1 WO 2009137525A1
Authority
WO
WIPO (PCT)
Prior art keywords
ophthalmic device
device material
weight
ethylene oxide
block copolymer
Prior art date
Application number
PCT/US2009/042903
Other languages
French (fr)
Inventor
Chance Lehman
Charles Freeman
Original Assignee
Alcon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon, Inc. filed Critical Alcon, Inc.
Priority to CA2722784A priority Critical patent/CA2722784A1/en
Priority to AU2009244393A priority patent/AU2009244393A1/en
Priority to EP09743511A priority patent/EP2274640B1/en
Priority to BRPI0912520A priority patent/BRPI0912520A2/en
Priority to MX2010012098A priority patent/MX2010012098A/en
Priority to JP2011508613A priority patent/JP2011519685A/en
Priority to CN2009801163130A priority patent/CN102016649A/en
Priority to ES09743511T priority patent/ES2375608T3/en
Priority to AT09743511T priority patent/ATE536559T1/en
Publication of WO2009137525A1 publication Critical patent/WO2009137525A1/en
Priority to IL208727A priority patent/IL208727A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/14Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • A61F2/16Intraocular lenses
    • A61F2/1613Intraocular lenses having special lens configurations, e.g. multipart lenses; having particular optical properties, e.g. pseudo-accommodative lenses, lenses having aberration corrections, diffractive lenses, lenses for variably absorbing electromagnetic radiation, lenses having variable focus
    • A61F2/1616Pseudo-accommodative, e.g. multifocal or enabling monovision
    • GPHYSICS
    • G02OPTICS
    • G02BOPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B1/00Optical elements characterised by the material of which they are made; Optical coatings for optical elements
    • G02B1/04Optical elements characterised by the material of which they are made; Optical coatings for optical elements made of organic materials, e.g. plastics
    • G02B1/041Lenses
    • G02B1/043Contact lenses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/14Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • A61F2/16Intraocular lenses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof

Definitions

  • This invention relates to high refractive index polymers and their use in ophthalmic lenses, particularly intraocular lenses that can be inserted through small incisions.
  • High refractive index acrylic materials are known for use in intraocular lenses (lOLs).
  • lOLs intraocular lenses
  • U.S. Patent No. 5,290,892 discloses high refractive index acrylic materials suitable for use as IOL materials. The materials are foldable and thus capable of being inserted through small incisions. These acrylic materials contain, as principal components, two aryl acrylic monomers.
  • foldable acrylic intraocular lenses develop "glistenings" or “vacuoles” when implanted in humans or soaked in water at physiological temperatures. These microvacuoles appear to be pockets of water approximately 1 ⁇ m or greater in diameter. Glistenings are often too small to be seen by the naked eye, but are sometimes observed using a slit-lamp. Although glistenings have no detrimental effect on the function or performance of IOLs made from acrylic materials, it is nevertheless cosmetically desirable to minimize or eliminate them.
  • ophthalmic device materials including IOL materials, containing less than 15% by weight of certain polymerizable surfactants.
  • the polymerizable surfactants are poloxamers and poloxamines, which are generally available under the PLURONIC and TETRONIC tradenames.
  • One advantage of adding such polymerizable surfactants as comonomers in forming polymeric devices is said to be changed or improved device surface properties, such as lipid or protein uptake. It was determined that the functionalized surfactants did not affect mechanical properties of the device materials as the addition of the polymerizable surfactants produced no real change in the modulus or tear strength (see Example 17 of 2006/0275342 A1).
  • the surfactants are chemically modified to make them polymerizable as comonomers.
  • unmodified surfactants were incorporated into a hydrogel contact lens material during polymerization, it was noted that upon hydration the lenses would become cloudy.
  • methacrylated counterparts of the unmodified surfactants were used, however, optical clarity was maintained after hydration (see Example 16 and Figures 6 - 8 of 2006/0275342 A1).
  • the ophthalmic device materials comprise a) device forming monomers consisting essentially of a single polymerizable monomer of the structure:
  • Z is H or CH 3 ;
  • X is (CH 2 )m or 0(CH 2 CH 2 O) n ; m is 2 - 6; n is 1 - 6; and
  • Ar is phenyl which can be unsubstituted or substituted with CH3,
  • These device materials can be used to form intraocular lenses that have high refractive indexes, are flexible and transparent, can be inserted into the eye through a relatively small incision, and recover their original shape after having been inserted. Moreover, IOLs made from these materials are free or substantially free of glistenings compared to otherwise identical materials lacking the non-polymerizable surfactant.
  • the present invention is based upon the finding that the ophthalmic device materials obtained by copolymerizing one monomer of structure (I) and a cross-linking agent with the specified non-polymerizable surfactants are clear. Additionally, unlike when other propylene oxide-ethylene oxide-propylene oxide block copolymer surfactants are added to a monomer of structure (I) to obtain ophthalmic device materials, when a non-polymerizable propylene oxide-ethylene oxide-propylene oxide block copolymer surfactant having an average molecular weight of approximately 3600 and an ethylene oxide unit content of approximately 40% by weight or a non-polymerizable ethylene oxide-propylene oxide-ethylene oxide block copolymer surfactant having an average molecular weight of approximately 5900 and an ethylene oxide content of approximately 40% by weight is added, the device materials are free or substantially free of glistenings.
  • the ophthalmic device materials of the present invention comprise device forming monomers consisting essentially of a single monomer of the structure: Z
  • Z is H or CH 3 ;
  • X is (CH 2 )m or 0(CH 2 CH 2 O) n ; m is 2 - 6; n is 1 - 6; and
  • Ar is phenyl which can be unsubstituted or substituted with CH3,
  • Monomers of structure (I) can be made by methods known in the art.
  • the conjugate alcohol of the desired monomer can be combined in a reaction vessel with methyl acrylate, tetrabutyl titanate (catalyst), and a polymerization inhibitor such as 4-benzyloxy phenol.
  • the vessel can then be heated to facilitate the reaction and distill off the reaction by-products to drive the reaction to completion.
  • Alternative synthesis schemes involve adding acrylic acid to the conjugate alcohol and catalyzing with a carbodiimide or mixing the conjugate alcohol with acryloyl chloride and a base such as pyridine or triethylamine.
  • Suitable monomers of structure (I) include, but are not limited to: 2- phenoxyethyl acrylate; 3-phenoxypropyl acrylate; 4-phenoxybutyl acrylate; polyethylene glycol phenyl ether acrylate; and their corresponding methacrylates.
  • Preferred monomers of structure (I) are those wherein X is (CH 2 ) m ; rn is 2 - 4, and Ar is phenyl. Most preferred is 2-phenoxyethyl acrylate.
  • the total amount of the monomer of structure (I) contained in the device materials of the present invention is generally about 75% by weight or more, and is preferably about 80 - 90 % by weight, of the total amount of polymerizable components of the ophthalmic device materials. Most preferably, the total amount of monomer of structure (I) contained in the device materials of the present invention is 87 - 90 % by weight.
  • the ophthalmic device materials of the present invention also contain a polymerizable cross-linking agent.
  • the cross-linking agent may be any terminally ethylenically unsaturated compound having more than one unsaturated group.
  • Suitable cross-linking agents include, for example:
  • ethylene glycol dimethacrylate diethylene glycol dimethacrylate, allyl methacrylate, 1 ,3-propanediol dimethacrylate, allyl methacrylate, 1 ,6- hexanediol dimethacrylate, 1 ,4-butanediol dimethacrylate, and their corresponding acrylates.
  • Preferred cross-linking agents are ethylene glycol dimethacrylate (EGDMA); 1 ,4-butanediol diacrylate (BDDA); and 1 ,6-
  • the amount of any cross-linking agent used in the device materials of the present invention will be 5 % by weight or less, preferably 1 - 2 % by weight, of the polymerizable components of the ophthalmic device materials.
  • the copolymers of the present invention also contain a non- polymerizable block copolymer surfactant selected from the group consisting of: a propylene oxide-ethylene oxide-propylene oxide block copolymer surfactant having an average molecular weight of approximately 3600 and an ethylene
  • D amount of non-polymerizable block copolymer surfactant contained in the ophthalmic device materials of the present invention is generally 5 - 15 % by weight, and is preferably 9 - 11 % by weight.
  • the proportions of the monomers to be included in the copolymers of the present invention are preferably chosen so that the copolymer has a glass transition temperature (T 9 ) not greater than about 37 0 C, which is normal human body temperature. Copolymers having glass transition temperatures higher than 37 0 C are not suitable for use in foldable 10Ls; such lenses could only be rolled or folded at temperatures above 37 0 C and would not unroll or unfold at normal body temperature.
  • copolymers having a glass transition temperature somewhat below normal body temperature and no greater than normal room temperature e.g., about 20 - 25 ° C, in order that IOLs made of such copolymers can be rolled or folded conveniently at room temperature.
  • T 9 is measured by differential scanning calorimetry at 10 °C/min., and is determined at the midpoint of the transition of the heat flux curve.
  • the materials of the present invention preferably exhibit sufficient strength to allow devices made of them to be folded or manipulated without fracturing.
  • the copolymers of the present invention will have an elongation of at least 80%, preferably at least 100%, and most preferably between 110 and 200%. This property indicates that lenses made of such materials generally will not crack, tear or split when folded. Elongation of polymer samples is determined on dumbbell shaped tension test specimens with a 20 mm total length, length in the grip area of 4.88 mm, overall width of 2.49 mm, 0.833 mm width of the narrow section, a fillet radius of 8.83 mm, and a thickness of 0.9 mm.
  • the materials of the present invention When the ophthalmic device materials of the present invention are used to make 1OLs, the materials preferably have a refractive index of 1.53 or greater in the fully hydrated state as measured by a refractometer at 37°C ⁇ 2°C.
  • IOLs made of the ophthalmic device materials of the present invention are free or substantially free of glistenings when measured according to the following test ("the Glistening Test").
  • the presence of glistenings is measured by placement of a lens or disk sample into a vial and adding deionized water or a balanced salt solution.
  • the vial is then placed into a water bath preheated to 45 0 C. Samples are to be maintained in the bath for 24 ⁇ 2 hours.
  • the vial is then removed from the water bath and allowed to equilibrate at room temperature for 2 ⁇ 0.5 hours.
  • the sample is removed from the vial and placed on a microscope slide. The sample is inspected visually in various on angle or off angle lighting to evaluate clarity.
  • Visualization of glistenings is done with light microscopy using a magnification of 10 to 100x.
  • a sample is judged to be free of glistenings if, at 10 - 100x magnification, the number of glistenings detected in the eyepiece is zero.
  • a sample is judged to be substantially free of glistenings if, at 10 - 100x magnification, the number of glistenings detected in the eyepiece is less than about 2/mm 3 .
  • the sample is rastered throughout the entire volume of the lens, varying the magnification levels (10 - 100x), the aperture iris diaphragm, and the field conditions (using both bright field and dark field conditions) in an attempt to detect the presence of glistenings.
  • the ultraviolet absorbing material may also be included in the materials of the present invention.
  • the ultraviolet absorbing material can be any compound which absorbs ultraviolet light, i.e., light having a wavelength shorter than about 400 nm, but does not absorb any substantial amount of visible light.
  • the ultraviolet absorbing compound is incorporated into the monomer mixture and is entrapped in the polymer matrix when the monomer mixture is polymerized.
  • Suitable ultraviolet absorbing compounds include substituted benzophenones, such as 2-hydroxybenzophenone, and 2-(2- hydroxyphenyl)benzotriazoles. It is preferred to use an ultraviolet absorbing i compound which is copolymerizable with the monomers and is thereby covalently bound to the polymer matrix. In this way possible leaching of the ultraviolet absorbing compound out of the lens and into the interior of the eye is minimized.
  • Suitable copolymerizable ultraviolet absorbing compounds are the substituted 2-hydroxybenzophenones disclosed in U.S. Patent No. 4,304,895
  • the most preferred ultraviolet absorbing compounds are 2-(2'- hydroxy-3'-methallyl-5'-methyl phenyl) benzotriazole and 2-(3'-ferf-butyl-2'- hydroxy-5'-methacryloylpropoxyphenyl)-5-methoxy-2H-benzotriazole
  • ophthalmic devices made of the copolymers of the present invention may include colored dyes, such as the yellow dyes disclosed in U.S. Patent No. 5,470,932.
  • copolymers of this invention are prepared by conventional means.
  • the mixture can then be introduced into a mold of desired shape, and the polymerization s carried out by heating to activate the initiator.
  • Typical thermal free radical initiators include peroxides, such as benzophenone peroxide, peroxycarbonates, such as bis-(4-t-butylcyclohexyl) peroxydicarbonate, azonitriles, such as azobisisobutyronitrile, and the like.
  • a preferred initiator is ferf-butyl peroxy-2-ethylhexanoate (T21s).
  • the monomers can benzophenone peroxide, peroxycarbonates, such as bis-(4-t-butylcyclohexyl) peroxy
  • Conventional photoinitiator compounds e.g., a benzophenone-type photoinitiator, can also be introduced to facilitate the polymerization.
  • the ophthalmic device materials of the present invention are extracted in a suitable solvent to remove as much of the unreacted components of the materials as possible.
  • suitable solvents include acetone, methanol, and cyclohexane.
  • a preferred solvent for extraction is acetone.
  • IOLs constructed of the disclosed ophthalmic device materials can be of any design capable of being rolled or folded into a small cross section that can fit through a relatively smaller incision.
  • the IOLs can be of what is known as a one piece or multipiece design.
  • an IOL comprises an optic and at least one haptic.
  • the optic is that portion which serves as the lens and the haptics are attached to the optic and are like arms which hold the optic in its proper place in the eye.
  • the optic and haptic(s) can be of the same or different material.
  • a multipiece lens is so called because the optic and the haptic(s) are made separately and then the haptics are attached to the optic.
  • the optic and the haptics are formed out of one piece of material. Depending on the material, the haptics are then cut, or lathed, out of the material to produce the IOL.
  • the ophthalmic device materials of the present invention are also suitable for use in other devices, including contact lenses, keratoprostheses, intracorneal lenses, corneal inlays or rings, and glaucoma filtration devices.
  • EXAMPLE 1 The device materials identified in Table 1 below were prepared by dissolving the indicated ingredients in a 20 ml glass vial and mixing them with a vortex mixer.
  • POEA 2-phenoxyethyl acrylate.
  • BDDA 1 ,4-butanediol diacrylate.
  • R1 Pluronic surfactant type by BASF tradename.
  • Tensile bar specimens in the fashion of "dogbones" were cut from each sample group using a die and press. Typically, 3 specimens per slab were prepared and 9 total specimens per formulation. Tensile properties were measured using an lnstron 5543 extensometer at 500mm/min crosshead speed. Stress at break, % strain at break, Young's modulus, the 25% secant modulus, and 100% secant modulus data were obtained. The results are shown in Table 3.

Abstract

High refractive index copolymers suitable for use in ophthalmic devices are disclosed. The copolymers comprise a single aryl hydrophobic monomer as a device forming monomer. In addition, the copolymers comprise a non-polymerizable block copolymer surfactant. The copolymers have a reduced tendency to form glistenings when stored in water at physiological temperatures.

Description

HIGH REFRACTIVE INDEX OPHTHALMIC DEVICE MATERIALS
FIELD OF THE INVENTION
This invention relates to high refractive index polymers and their use in ophthalmic lenses, particularly intraocular lenses that can be inserted through small incisions.
BACKGROUND OF THE INVENTION
High refractive index acrylic materials are known for use in intraocular lenses (lOLs). For example, U.S. Patent No. 5,290,892 discloses high refractive index acrylic materials suitable for use as IOL materials. The materials are foldable and thus capable of being inserted through small incisions. These acrylic materials contain, as principal components, two aryl acrylic monomers.
In some cases, foldable acrylic intraocular lenses develop "glistenings" or "vacuoles" when implanted in humans or soaked in water at physiological temperatures. These microvacuoles appear to be pockets of water approximately 1 μm or greater in diameter. Glistenings are often too small to be seen by the naked eye, but are sometimes observed using a slit-lamp. Although glistenings have no detrimental effect on the function or performance of IOLs made from acrylic materials, it is nevertheless cosmetically desirable to minimize or eliminate them.
Published U.S. Patent Application 2006/0275342 A1 discloses ophthalmic device materials, including IOL materials, containing less than 15% by weight of certain polymerizable surfactants. The polymerizable surfactants are poloxamers and poloxamines, which are generally available under the PLURONIC and TETRONIC tradenames. One advantage of adding such polymerizable surfactants as comonomers in forming polymeric devices is said to be changed or improved device surface properties, such as lipid or protein uptake. It was determined that the functionalized surfactants did not affect mechanical properties of the device materials as the addition of the polymerizable surfactants produced no real change in the modulus or tear strength (see Example 17 of 2006/0275342 A1). The surfactants are chemically modified to make them polymerizable as comonomers. When unmodified surfactants were incorporated into a hydrogel contact lens material during polymerization, it was noted that upon hydration the lenses would become cloudy. When methacrylated counterparts of the unmodified surfactants were used, however, optical clarity was maintained after hydration (see Example 16 and Figures 6 - 8 of 2006/0275342 A1).
SUMMARY OF THE INVENTION
This invention is directed to ophthalmic device materials that do not contain glistenings. The ophthalmic device materials comprise a) device forming monomers consisting essentially of a single polymerizable monomer of the structure:
Z
I
CH2 = C - COO -X-O-Ar
wherein: Z is H or CH3;
X is (CH2)m or 0(CH2CH2O)n; m is 2 - 6; n is 1 - 6; and
Ar is phenyl which can be unsubstituted or substituted with CH3,
C2H5, n-C3H7, JSo-C3H7, OCH3, C6H1 1 , Cl, Br, C6H5, or CH2C6H5; b) a polymerizable cross-linking agent; and c) a non-polymerizable propylene oxide-ethylene oxide-propylene oxide block copolymer surfactant having a molecular weight (average) of approximately 3600 and an ethylene oxide unit content of approximately 40% by weight or a non-polymerizable ethylene oxide-propylene oxide-ethylene oxide block copolymer surfactant having a molecular weight (average) of approximately 5900 and an ethylene oxide unit content of approximately 40% by weight.
These device materials can be used to form intraocular lenses that have high refractive indexes, are flexible and transparent, can be inserted into the eye through a relatively small incision, and recover their original shape after having been inserted. Moreover, IOLs made from these materials are free or substantially free of glistenings compared to otherwise identical materials lacking the non-polymerizable surfactant.
Among other factors, the present invention is based upon the finding that the ophthalmic device materials obtained by copolymerizing one monomer of structure (I) and a cross-linking agent with the specified non-polymerizable surfactants are clear. Additionally, unlike when other propylene oxide-ethylene oxide-propylene oxide block copolymer surfactants are added to a monomer of structure (I) to obtain ophthalmic device materials, when a non-polymerizable propylene oxide-ethylene oxide-propylene oxide block copolymer surfactant having an average molecular weight of approximately 3600 and an ethylene oxide unit content of approximately 40% by weight or a non-polymerizable ethylene oxide-propylene oxide-ethylene oxide block copolymer surfactant having an average molecular weight of approximately 5900 and an ethylene oxide content of approximately 40% by weight is added, the device materials are free or substantially free of glistenings.
DETAILED DESCRIPTION OF THE INVENTION
The ophthalmic device materials of the present invention comprise device forming monomers consisting essentially of a single monomer of the structure: Z
I
CH2 = C - COO -X-O-Ar
(I)
wherein: Z is H or CH3;
X is (CH2)m or 0(CH2CH2O)n; m is 2 - 6; n is 1 - 6; and
Ar is phenyl which can be unsubstituted or substituted with CH3,
C2H5, n-C3H7, JSO-C3H7, OCH3, C6H1 1 , Cl, Br, C6H5, or CH2C6H5;
Monomers of structure (I) can be made by methods known in the art.
For example, the conjugate alcohol of the desired monomer can be combined in a reaction vessel with methyl acrylate, tetrabutyl titanate (catalyst), and a polymerization inhibitor such as 4-benzyloxy phenol. The vessel can then be heated to facilitate the reaction and distill off the reaction by-products to drive the reaction to completion. Alternative synthesis schemes involve adding acrylic acid to the conjugate alcohol and catalyzing with a carbodiimide or mixing the conjugate alcohol with acryloyl chloride and a base such as pyridine or triethylamine.
Suitable monomers of structure (I) include, but are not limited to: 2- phenoxyethyl acrylate; 3-phenoxypropyl acrylate; 4-phenoxybutyl acrylate; polyethylene glycol phenyl ether acrylate; and their corresponding methacrylates.
Preferred monomers of structure (I) are those wherein X is (CH2)m; rn is 2 - 4, and Ar is phenyl. Most preferred is 2-phenoxyethyl acrylate.
The total amount of the monomer of structure (I) contained in the device materials of the present invention is generally about 75% by weight or more, and is preferably about 80 - 90 % by weight, of the total amount of polymerizable components of the ophthalmic device materials. Most preferably, the total amount of monomer of structure (I) contained in the device materials of the present invention is 87 - 90 % by weight.
The ophthalmic device materials of the present invention also contain a polymerizable cross-linking agent. The cross-linking agent may be any terminally ethylenically unsaturated compound having more than one unsaturated group. Suitable cross-linking agents include, for example:
) ethylene glycol dimethacrylate, diethylene glycol dimethacrylate, allyl methacrylate, 1 ,3-propanediol dimethacrylate, allyl methacrylate, 1 ,6- hexanediol dimethacrylate, 1 ,4-butanediol dimethacrylate, and their corresponding acrylates. Preferred cross-linking agents are ethylene glycol dimethacrylate (EGDMA); 1 ,4-butanediol diacrylate (BDDA); and 1 ,6-
> hexanediol diacrylate. In general, the amount of any cross-linking agent used in the device materials of the present invention will be 5 % by weight or less, preferably 1 - 2 % by weight, of the polymerizable components of the ophthalmic device materials.
3 In addition to the single monomer of structure (I) and a cross-linking agent, the copolymers of the present invention also contain a non- polymerizable block copolymer surfactant selected from the group consisting of: a propylene oxide-ethylene oxide-propylene oxide block copolymer surfactant having an average molecular weight of approximately 3600 and an ethylene
5 oxide unit content of approximately 40% by weight and an ethylene oxide- propylene oxide-ethylene oxide block copolymer surfactant having an average molecular weight of approximately 5900 and a ethylene oxide unit content of approximately 40% by weight. Such surfactants are commercially available from BASF under the tradenames Pluronic® 25R4 and Pluronic® P104. The
D amount of non-polymerizable block copolymer surfactant contained in the ophthalmic device materials of the present invention is generally 5 - 15 % by weight, and is preferably 9 - 11 % by weight. The proportions of the monomers to be included in the copolymers of the present invention are preferably chosen so that the copolymer has a glass transition temperature (T9) not greater than about 37 0C, which is normal human body temperature. Copolymers having glass transition temperatures higher than 37 0C are not suitable for use in foldable 10Ls; such lenses could only be rolled or folded at temperatures above 37 0C and would not unroll or unfold at normal body temperature. It is preferred to use copolymers having a glass transition temperature somewhat below normal body temperature and no greater than normal room temperature, e.g., about 20 - 25 °C, in order that IOLs made of such copolymers can be rolled or folded conveniently at room temperature. T9 is measured by differential scanning calorimetry at 10 °C/min., and is determined at the midpoint of the transition of the heat flux curve.
For IOLs and other implant applications, the materials of the present invention preferably exhibit sufficient strength to allow devices made of them to be folded or manipulated without fracturing. Thus the copolymers of the present invention will have an elongation of at least 80%, preferably at least 100%, and most preferably between 110 and 200%. This property indicates that lenses made of such materials generally will not crack, tear or split when folded. Elongation of polymer samples is determined on dumbbell shaped tension test specimens with a 20 mm total length, length in the grip area of 4.88 mm, overall width of 2.49 mm, 0.833 mm width of the narrow section, a fillet radius of 8.83 mm, and a thickness of 0.9 mm. Testing is performed on samples at ambient conditions using an lnstron Material Tester (Model No. 4442 or equivalent) with a 50 Netwon load cell. The grip distance is set at 14 mm and a crosshead speed is set at 500 mm/minute and the sample is pulled until failure. The elongation (strain) is reported as a fraction of the displacement at failure to the original grip distance. Since the materials to be tested are essentially soft elastomers, loading them into the lnstron machine tends to make them buckle. To remove the slack in the material sample a pre-load is placed upon the sample. This helps to reduce the slack and provide a more consistent reading. Once the sample is pre-loaded to a desired value (typically 0.03 to 0.05 N) the strain is set to zero and the test begun.
When the ophthalmic device materials of the present invention are used to make 1OLs, the materials preferably have a refractive index of 1.53 or greater in the fully hydrated state as measured by a refractometer at 37°C ± 2°C.
IOLs made of the ophthalmic device materials of the present invention are free or substantially free of glistenings when measured according to the following test ("the Glistening Test"). The presence of glistenings is measured by placement of a lens or disk sample into a vial and adding deionized water or a balanced salt solution. The vial is then placed into a water bath preheated to 45 0C. Samples are to be maintained in the bath for 24 ± 2 hours. The vial is then removed from the water bath and allowed to equilibrate at room temperature for 2 ± 0.5 hours. The sample is removed from the vial and placed on a microscope slide. The sample is inspected visually in various on angle or off angle lighting to evaluate clarity. Visualization of glistenings is done with light microscopy using a magnification of 10 to 100x. A sample is judged to be free of glistenings if, at 10 - 100x magnification, the number of glistenings detected in the eyepiece is zero. A sample is judged to be substantially free of glistenings if, at 10 - 100x magnification, the number of glistenings detected in the eyepiece is less than about 2/mm3. It is often very difficult to detect glistenings, so the sample is rastered throughout the entire volume of the lens, varying the magnification levels (10 - 100x), the aperture iris diaphragm, and the field conditions (using both bright field and dark field conditions) in an attempt to detect the presence of glistenings.
An ultra-violet absorbing material may also be included in the materials of the present invention. The ultraviolet absorbing material can be any compound which absorbs ultraviolet light, i.e., light having a wavelength shorter than about 400 nm, but does not absorb any substantial amount of visible light.
The ultraviolet absorbing compound is incorporated into the monomer mixture and is entrapped in the polymer matrix when the monomer mixture is polymerized. Suitable ultraviolet absorbing compounds include substituted benzophenones, such as 2-hydroxybenzophenone, and 2-(2- hydroxyphenyl)benzotriazoles. It is preferred to use an ultraviolet absorbing i compound which is copolymerizable with the monomers and is thereby covalently bound to the polymer matrix. In this way possible leaching of the ultraviolet absorbing compound out of the lens and into the interior of the eye is minimized. Suitable copolymerizable ultraviolet absorbing compounds are the substituted 2-hydroxybenzophenones disclosed in U.S. Patent No. 4,304,895
) and the 2-hydroxy-5-acryloxyphenyl-2H-benzotriazoles disclosed in U.S. Patent No. 4,528,311. The most preferred ultraviolet absorbing compounds are 2-(2'- hydroxy-3'-methallyl-5'-methyl phenyl) benzotriazole and 2-(3'-ferf-butyl-2'- hydroxy-5'-methacryloylpropoxyphenyl)-5-methoxy-2H-benzotriazole
i In addition to ultraviolet absorbing materials, ophthalmic devices made of the copolymers of the present invention may include colored dyes, such as the yellow dyes disclosed in U.S. Patent No. 5,470,932.
The copolymers of this invention are prepared by conventional
) polymerization methods. For example, a mixture of the liquid monomer of structure (I) and a cross-linking agent in the desired proportions, together with one of the specified non-polymerizable surfactants, a UV absorber, a yellow dye, and a conventional thermal free-radical initiator, is prepared. The mixture can then be introduced into a mold of desired shape, and the polymerization s carried out by heating to activate the initiator. Typical thermal free radical initiators include peroxides, such as benzophenone peroxide, peroxycarbonates, such as bis-(4-t-butylcyclohexyl) peroxydicarbonate, azonitriles, such as azobisisobutyronitrile, and the like. A preferred initiator is ferf-butyl peroxy-2-ethylhexanoate (T21s). Alternatively, the monomers can be
) photopolymerized by using a mold which is transparent to actinic radiation of a wavelength capable of initiating polymerization of these acrylic monomers by itself. Conventional photoinitiator compounds, e.g., a benzophenone-type photoinitiator, can also be introduced to facilitate the polymerization.
Once the ophthalmic device materials of the present invention have been cured, they are extracted in a suitable solvent to remove as much of the unreacted components of the materials as possible. Examples of suitable solvents include acetone, methanol, and cyclohexane. A preferred solvent for extraction is acetone.
IOLs constructed of the disclosed ophthalmic device materials can be of any design capable of being rolled or folded into a small cross section that can fit through a relatively smaller incision. For example, the IOLs can be of what is known as a one piece or multipiece design. Typically, an IOL comprises an optic and at least one haptic. The optic is that portion which serves as the lens and the haptics are attached to the optic and are like arms which hold the optic in its proper place in the eye. The optic and haptic(s) can be of the same or different material. A multipiece lens is so called because the optic and the haptic(s) are made separately and then the haptics are attached to the optic. In a single piece lens, the optic and the haptics are formed out of one piece of material. Depending on the material, the haptics are then cut, or lathed, out of the material to produce the IOL.
In addition to IOLs, the ophthalmic device materials of the present invention are also suitable for use in other devices, including contact lenses, keratoprostheses, intracorneal lenses, corneal inlays or rings, and glaucoma filtration devices.
The invention will be further illustrated by the following examples which are intended to be illustrative, but not limiting.
EXAMPLE 1 The device materials identified in Table 1 below were prepared by dissolving the indicated ingredients in a 20 ml glass vial and mixing them with a vortex mixer. POEA = 2-phenoxyethyl acrylate. BDDA = 1 ,4-butanediol diacrylate. L31 , L43, L61 , L64, L81 , L92, L101 , F87, F88, F98, F127, P84, P104, 10R5, 17R2, 17R4, 25R2, 25R4, 31 R1 = Pluronic surfactant type by BASF tradename. Each formulation was purged with nitrogen for 2 minutes, placed under high vacuum (<0.5 mm Hg) for 2 minutes, injected through a 0.2 micron PTFE filter into standard polypropylene slab molds, and then heated at 70 0C for 2 hours, ramped to 110 0C during 10 minutes, and post cured at 1 10 0C for 1 hour. Three - five slabs were weighed for % extractables. The polymer slabs were extracted in acetone for at least 16 hours at ambient temperature with one solvent change out after the first hour, and then allowed to dry while covered with aluminum foil at ambient temperature for 8 hours. Slabs were further dried under reduced atmosphere at 60 0C for at least 16 hours. Slabs were removed and cooled to room temperature. Previously weighed slabs were weighed again for % extractables. Slabs were hydrated in a water bath at room temperature and 35°C and the equilibrium water content ("% EWC") at each temperature was determined. The results are shown in Table 2.
Table 1 Device Materials
Figure imgf000012_0001
Table 2 % extractables and % EWC
Sample % ext SD (±) % EWC (23C) SD (±) % EWC (35C) SD (±)
L31 13 80% 0 14% 0 68% 0 09% 0 60% 0 08%
L43 14 21% 0 09% 0 82% 0 18% 0 77% 0 14%
L61
L64 13 48% 0 27% 0 95% 0 34% 0 77% 0 20%
L81 13 66% 0 27% 0 93% 0 07% 0 89% 0 15%
L92 13 21% 0 17% 1 05% 0 10% 1 01% 0 06%
L101 13 62% 0 22% 1 11 % 0 03% 1 16% 0 12%
F87 11 20% 0 92% 2 87% 0 24% 2 63% 0 26%
F88 9 77% 0 40% 3 88% 0 12% 4 31% 0 16%
F98 9 16% 0 38% 4 42% 0 21 % 5 26% 0 27%
F127 9 55% 0 65% 4 09% 0 09% 4 42% 0 11 %
P84 12 47% 042% 0 89% 0 16% 0 38% 028%
P104 12 18% 0 13% 1 48% 0 03% 1 04% 0 09%
10R5 14 12% 0 43% 0 44% 0 05% 0 12% 0 22%
17R2 12 96% 0 23% 0 40% 0 04% 0 10% 0 10%
17R4 13 68% 0 38% 0 39% 0 06% 0 22% 0 19%
25R2 13 60% 0 33% 0 54% 0 08% 0 28% 0 02%
25R4 13 45% 0 40% 0 73% 0 04% 0 41% 0 16%
31 R1 13 58% 0 24% 0 61% 0 06% 0 19% 0 09%
Ctrl 5 62% 0 17% 0 25% 0 14% 0 00%
Tensile bar specimens in the fashion of "dogbones" were cut from each sample group using a die and press. Typically, 3 specimens per slab were prepared and 9 total specimens per formulation. Tensile properties were measured using an lnstron 5543 extensometer at 500mm/min crosshead speed. Stress at break, % strain at break, Young's modulus, the 25% secant modulus, and 100% secant modulus data were obtained. The results are shown in Table 3.
Table 3 Tensile properties
Stress at Strain at Young's 25% 100% Break Break Modulus Secant Secant
Sample Modulus Modulus
(MPa) SD (±) (%) SD (±) (MPa SD ± MPa SD (±) MPa SD (±)
Figure imgf000014_0001
Six mm disks from three separate slabs per lot of material were prepared for microvacuole testing. Disks were placed into 2OmL vials containing ~20ml_ deionized water and incubated in a water bath at 45°C for 24 hours. The sample vials were removed from the water bath and placed on the lab bench to cool to room temperature, typically 22 - 24°C. Each disk was imaged using an Olympus BX60 microscope under bright field (BF) and dark field (DFA) settings at 10x with a 2x magnifier. Samples were imaged after 4 hours and again after 2 weeks at 22 - 24 0C. The results are shown in Tables 4 and 5. The abbreviation "nd" in Tables 4 and 5 means "none detected."
Table 4 MV testing post 4hrs at ~22°C
Figure imgf000015_0001
Table 5 MV testing post 2 weeks at ~22°C
The invention having now been fully described, it should be understood that it may be embodied in other specific forms or variations without departing from its spirit or essential characteristics. Accordingly, the embodiments described above are to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are intended to be embraced therein.

Claims

WE CLAIM:
1. An ophthalmic device material comprising a) device-forming monomers consisting essentially of a single polymerizable monomer of the structure:
Z
I
CH2 = C - COO -X-O-Ar (I)
wherein: Z is H or CH3;
X is (CH2)m or 0(CH2CH2O)n; m is 2 - 6; n is 1 - 6; and Ar is phenyl which can be unsubstituted or substituted with CH3,
C2H5, n-C3H7, JSO-C3H7, OCH3, C6H11, Cl, Br, C6H5, or CH2C6H5; b) a polymerizable cross-linking agent; and c) a non-polymerizable block copolymer surfactant selected from the group consisting of: a propylene oxide-ethylene oxide-propylene oxide block copolymer surfactant having an average molecular weight of approximately 3600 and an ethylene oxide unit content of approximately 40% by weight, and an ethylene oxide-propylene oxide-ethylene oxide block copolymer surfactant having an average molecular weight of approximately 5900 and a ethylene oxide unit content of approximately 40% by weight.
2. The ophthalmic device material of Claim 1 wherein the monomer of structure (I) is selected from the group consisting of: 2-phenoxyethyl acrylate; 3- phenoxypropyl acrylate; 4-phenoxybutyl acrylate; polyethylene glycol phenyl ether acrylate; and their corresponding methacrylates.
3. The ophthalmic device material of Claim 1 wherein X is (CH2)m; m is 2 - 4; and Ar is phenyl.
4. The ophthalmic device material of Claim 3 wherein the single monomer of structure (I) is 2-phenyloxyethyl acrylate.
5. The ophthalmic device material of Claim 1 wherein the amount of monomer of structure (I) is at least 75% by weight.
6. The ophthalmic device material of Claim 5 wherein the amount of monomer of structure (I) is 80 - 90 % by weight.
7. The ophthalmic device material of Claim 6 wherein the amount of monomer of structure (I) is 87 - 90 % by weight.
8. The ophthalmic device material of Claim 7 wherein the amount of non- polymerizable block copolymer surfactant is 5 - 15 % by weight.
9. The ophthalmic device material of Claim 8 wherein the amount of non- polymerizable block copolymer surfactant is 9 - 11 % by weight.
10. The ophthalmic device material of Claim 1 wherein the non- polymerizable block copolymer surfactant is a propylene oxide-ethylene oxide- propylene oxide block copolymer surfactant having an average molecular weight of approximately 3600 and an ethylene oxide unit content of approximately 40% by weight.
11. The ophthalmic device material of Claim 1 wherein the non- polymerizable block copolymer surfactant is an ethylene oxide-propylene oxide- ethylene oxide block copolymer surfactant having an average molecular weight of approximately 5900 and an ethylene oxide unit content of approximately 40% by weight.
12. The ophthalmic device material of Claim 1 further comprising an ultraviolet absorbing compound.
13. The ophthalmic device material of Claim 1 further comprising a blue-light blocking dye.
14. An ophthalmic device comprising the ophthalmic device material of Claim 1 , wherein the ophthalmic device is selected from the group consisting of: intraocular lenses; contact lenses; keratoprostheses; intracorneal lenses; and corneal inlays or rings.
PCT/US2009/042903 2008-05-06 2009-05-05 High refractive index ophthalmic device materials WO2009137525A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA2722784A CA2722784A1 (en) 2008-05-06 2009-05-05 High refractive index ophthalmic device materials
AU2009244393A AU2009244393A1 (en) 2008-05-06 2009-05-05 High refractive index ophthalmic device materials
EP09743511A EP2274640B1 (en) 2008-05-06 2009-05-05 High refractive index ophthalmic device materials
BRPI0912520A BRPI0912520A2 (en) 2008-05-06 2009-05-05 high refractive index ophthalmic device materials
MX2010012098A MX2010012098A (en) 2008-05-06 2009-05-05 High refractive index ophthalmic device materials.
JP2011508613A JP2011519685A (en) 2008-05-06 2009-05-05 High refractive index ophthalmic device materials
CN2009801163130A CN102016649A (en) 2008-05-06 2009-05-05 High refractive index ophthalmic device materials
ES09743511T ES2375608T3 (en) 2008-05-06 2009-05-05 MATERIALS FOR OFFICIAL DEVICES HIGH �? REFRACTION INDEX.
AT09743511T ATE536559T1 (en) 2008-05-06 2009-05-05 MATERIALS FOR HIGH REFRACTIVE INDEX OPHTHALMIC DEVICES
IL208727A IL208727A0 (en) 2008-05-06 2010-10-14 High refractive index ophthalmic device materials

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5086608P 2008-05-06 2008-05-06
US61/050,866 2008-05-06

Publications (1)

Publication Number Publication Date
WO2009137525A1 true WO2009137525A1 (en) 2009-11-12

Family

ID=40750983

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/042903 WO2009137525A1 (en) 2008-05-06 2009-05-05 High refractive index ophthalmic device materials

Country Status (16)

Country Link
US (1) US7790825B2 (en)
EP (1) EP2274640B1 (en)
JP (1) JP2011519685A (en)
KR (1) KR20110014614A (en)
CN (1) CN102016649A (en)
AR (1) AR071616A1 (en)
AT (1) ATE536559T1 (en)
AU (1) AU2009244393A1 (en)
BR (1) BRPI0912520A2 (en)
CA (1) CA2722784A1 (en)
ES (1) ES2375608T3 (en)
IL (1) IL208727A0 (en)
MX (1) MX2010012098A (en)
RU (1) RU2010149782A (en)
TW (1) TW201000155A (en)
WO (1) WO2009137525A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012004746A2 (en) 2010-07-05 2012-01-12 Polymer Technologies International (Eou) Refractive-diffractive ophthalmic device and compositions useful for producing same

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2225325B1 (en) 2007-07-25 2011-06-01 Alcon, Inc. High refractive index ophthalmic device materials
US8293858B1 (en) 2009-01-14 2012-10-23 Novartis Ag Ophthalmic and otorhinolaryngological device materials containing a reactive NVP macromer
US8148445B1 (en) 2009-01-14 2012-04-03 Novartis Ag Ophthalmic and otorhinolaryngological device materials containing a multi-arm PEG macromer
GB201003404D0 (en) 2010-03-01 2010-04-14 Contamac Ltd High refractive index polymer composition for opthalmic applications
US8362177B1 (en) 2010-05-05 2013-01-29 Novartis Ag High refractive index ophthalmic device materials with reduced tack
US9220590B2 (en) 2010-06-10 2015-12-29 Z Lens, Llc Accommodative intraocular lens and method of improving accommodation
TWI473823B (en) 2010-06-21 2015-02-21 Novartis Ag High refractive index, acrylic ophthalmic device materials with reduced glistenings
US8455572B2 (en) 2011-01-31 2013-06-04 Key Medical Technologies, Inc. Method of making ophthalmic devices and components thereof from hydrophobic acrylic (HA) polymers with reduced or eliminated glistenings
TWI517861B (en) * 2011-02-08 2016-01-21 諾華公司 Low-tack, hydrophobic ophthalmic device materials
KR101982897B1 (en) * 2011-09-16 2019-05-27 벤즈리써치앤드디벨롭먼트코오포레이숀 Hydrophobic intraocular lens
US9364318B2 (en) 2012-05-10 2016-06-14 Z Lens, Llc Accommodative-disaccommodative intraocular lens
CN105792860B (en) 2013-12-04 2019-06-04 诺华股份有限公司 Reflective soft acrylic material with high refractive index and minimum
US9921341B2 (en) 2014-12-16 2018-03-20 Novartis Ag Low-water content acrylate-acrylamide copolymers for ophthalmic devices
US9864102B2 (en) 2014-12-16 2018-01-09 Novartis Ag Hydrophobic acrylate-acrylamide copolymers for ophthalmic devices
ES2703566T3 (en) 2015-02-16 2019-03-11 Novartis Ag Wet packaging of intraocular lens materials with high refractive index
EP3503843B1 (en) 2016-08-24 2023-11-15 Carl Zeiss Meditec AG Dual mode accommodative-disacommodative intraocular lens
CA3108052A1 (en) * 2018-08-10 2020-02-13 Bausch & Lomb Incorporated High water content ophthalmic devices
CN113527567B (en) * 2021-07-26 2023-01-24 康小林 Hydrophobic non-glare high refractive index ophthalmic polymeric materials

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999008136A1 (en) * 1997-08-07 1999-02-18 Alcon Laboratories, Inc. Method of preparing foldable high refractive index acrylic ophthalmic device materials
WO1999053347A1 (en) * 1998-04-15 1999-10-21 Alcon Laboratories, Inc. High refractive index ophthalmic device materials
WO2001018078A1 (en) * 1999-09-07 2001-03-15 Alcon Universal Ltd. Foldable ophthalmic and otorhinolaryngological device materials
WO2001049240A2 (en) * 2000-01-05 2001-07-12 Novartis Ag Hydrogels
US20010037150A1 (en) * 2000-04-10 2001-11-01 Chan Kwan Y. Intraocular lens materials with low incidence of posterior capsule opacification
WO2004030715A1 (en) * 2002-09-30 2004-04-15 Bausch & Lomb Incorporated Bacterial attachment reduction to biomaterials and biomedical devices
WO2009015256A2 (en) * 2007-07-25 2009-01-29 Alcon, Inc. High refractive index ophthalmic device materials

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4304895A (en) 1973-06-20 1981-12-08 Wesley-Jessen, Inc. Ultraviolet absorbing corneal contact lenses
US4528311A (en) 1983-07-11 1985-07-09 Iolab Corporation Ultraviolet absorbing polymers comprising 2-hydroxy-5-acrylyloxyphenyl-2H-benzotriazoles
US4780488A (en) 1986-08-29 1988-10-25 Ciba-Geigy Corporation Wettable, flexible, oxygen permeable, substantially non-swellable contact lens containing polyoxyalkylene backbone units, and use thereof
US4857606A (en) 1987-06-05 1989-08-15 Ciga-Geigy Corporation Wettable, flexible, oxygen permeable, substantially non-swellable contact lens containing polyoxyalkylene backbone units, and use thereof
US5070169A (en) 1988-02-26 1991-12-03 Ciba-Geigy Corporation Wettable, flexible, oxygen permeable contact lens containing block copolymer polysiloxane-polyoxyalkylene backbone units and use thereof
US5070166A (en) 1988-02-26 1991-12-03 Su Kai C Wettable, flexible, oxygen permeable, contact lens containing polyoxyalkylene backbone units, and use thereof
US5070170A (en) 1988-02-26 1991-12-03 Ciba-Geigy Corporation Wettable, rigid gas permeable, substantially non-swellable contact lens containing block copolymer polysiloxane-polyoxyalkylene backbone units, and use thereof
US5039769A (en) 1989-10-11 1991-08-13 Ciba-Geigy Coproation Wettable, flexible, oxygen permeable, substantially non-swellable contact lens containing polyoxyalkylene backbone units, and use thereof
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
US5290892A (en) 1990-11-07 1994-03-01 Nestle S.A. Flexible intraocular lenses made from high refractive index polymers
US5470932A (en) 1993-10-18 1995-11-28 Alcon Laboratories, Inc. Polymerizable yellow dyes and their use in opthalmic lenses
PT1704878E (en) 1995-12-18 2013-07-17 Angiodevice Internat Gmbh Crosslinked polymer compositions and methods for their use
US6087415A (en) 1998-06-11 2000-07-11 Johnson & Johnson Vision Care, Inc. Biomedical devices with hydrophilic coatings
US6241766B1 (en) 1998-10-29 2001-06-05 Allergan Sales, Inc. Intraocular lenses made from polymeric compositions
US20060118493A9 (en) * 1998-12-09 2006-06-08 Chmelka Bradley F Block polymer processing for mesostructured inorganic oxide materials
US6329485B1 (en) 1998-12-11 2001-12-11 Bausch & Lomb Incorporated High refractive index hydrogel compositions for ophthalmic implants
US6281319B1 (en) 1999-04-12 2001-08-28 Surgidev Corporation Water plasticized high refractive index polymer for ophthalmic applications
US6271281B1 (en) 1999-08-26 2001-08-07 Medennium, Inc. Homopolymers containing stable elasticity inducing crosslinkers and ocular implants made therefrom
EP1249249A1 (en) 2000-12-12 2002-10-16 Menicon Co., Ltd. Ophthalmic composition
US6555030B1 (en) 2000-04-21 2003-04-29 Advanced Medical Optics, Inc. Method for making an accommodating intraocular lens
US20030017797A1 (en) * 2001-03-28 2003-01-23 Kendall Philip E. Dual cured abrasive articles
US6703466B1 (en) * 2001-06-18 2004-03-09 Alcon, Inc. Foldable intraocular lens optics having a glassy surface
US6939485B2 (en) 2001-10-30 2005-09-06 Randy Kish Method for shaping optical storage discs and products thereof
US7005031B2 (en) * 2002-01-16 2006-02-28 3M Innovative Properties Company Pressure sensitive adhesives having quaternary ammonium functionality, articles, and methods
US7550418B2 (en) * 2002-12-13 2009-06-23 Novartis Ag Lens care composition and method
US7037469B2 (en) 2003-03-19 2006-05-02 Bausch & Lomb, Inc. Method and composition for reducing contact lens swelling
US8197841B2 (en) 2004-12-22 2012-06-12 Bausch & Lomb Incorporated Polymerizable surfactants and their use as device forming comonomers
FR2893422B1 (en) * 2005-11-14 2008-03-07 Essilor Int OPHTHALMIC LENS COMPRISING A PROTECTIVE COATING AGAINST PHOTODEGRADATION AND METHOD FOR PREPARING SUCH AN OPHTHALMIC LENS.
US20070196329A1 (en) 2006-01-20 2007-08-23 Erning Xia Disinfection efficacy of lens care regimen for rigid gas permeable contact lenses

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999008136A1 (en) * 1997-08-07 1999-02-18 Alcon Laboratories, Inc. Method of preparing foldable high refractive index acrylic ophthalmic device materials
WO1999053347A1 (en) * 1998-04-15 1999-10-21 Alcon Laboratories, Inc. High refractive index ophthalmic device materials
WO2001018078A1 (en) * 1999-09-07 2001-03-15 Alcon Universal Ltd. Foldable ophthalmic and otorhinolaryngological device materials
WO2001049240A2 (en) * 2000-01-05 2001-07-12 Novartis Ag Hydrogels
US20010037150A1 (en) * 2000-04-10 2001-11-01 Chan Kwan Y. Intraocular lens materials with low incidence of posterior capsule opacification
WO2004030715A1 (en) * 2002-09-30 2004-04-15 Bausch & Lomb Incorporated Bacterial attachment reduction to biomaterials and biomedical devices
US20060205621A1 (en) * 2002-09-30 2006-09-14 Bausch & Lomb Incorporated Bacterial attachment reduction to biomaterials and biomedical devices
WO2009015256A2 (en) * 2007-07-25 2009-01-29 Alcon, Inc. High refractive index ophthalmic device materials

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012004746A2 (en) 2010-07-05 2012-01-12 Polymer Technologies International (Eou) Refractive-diffractive ophthalmic device and compositions useful for producing same
WO2012004744A2 (en) 2010-07-05 2012-01-12 Polymer Technologies International (Eou) Polymeric composition for ocular devices

Also Published As

Publication number Publication date
JP2011519685A (en) 2011-07-14
AR071616A1 (en) 2010-06-30
CN102016649A (en) 2011-04-13
IL208727A0 (en) 2010-12-30
CA2722784A1 (en) 2009-11-12
TW201000155A (en) 2010-01-01
EP2274640B1 (en) 2011-12-07
MX2010012098A (en) 2010-11-30
US20090281209A1 (en) 2009-11-12
BRPI0912520A2 (en) 2015-10-13
AU2009244393A1 (en) 2009-11-12
ATE536559T1 (en) 2011-12-15
ES2375608T3 (en) 2012-03-02
RU2010149782A (en) 2012-06-20
EP2274640A1 (en) 2011-01-19
KR20110014614A (en) 2011-02-11
US7790825B2 (en) 2010-09-07

Similar Documents

Publication Publication Date Title
US7790825B2 (en) High refractive index ophthalmic device materials
AU2011271228B2 (en) High refractive index, acrylic ophthalmic device materials with reduced glistenings
US7790824B2 (en) High refractive index ophthalmic device materials
CA2825359C (en) Low-tack, hydrophobic ophthalmic device materials
AU2012392512B2 (en) High refractive index ophthalmic device materials with reduced tack
US11576998B2 (en) High refractive index, high Abbe number intraocular lens materials
CA2928011A1 (en) Soft acrylic materials comprising a poly(phenylether)-containing monomer having a high refractive index and minimized glistening
US20130030079A1 (en) High refractive index ophthalmic device materials with reduced tack

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980116313.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09743511

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2140/MUMNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009743511

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009244393

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2722784

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2011508613

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/012098

Country of ref document: MX

Ref document number: 12010502499

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2009244393

Country of ref document: AU

Date of ref document: 20090505

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20107026665

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010149782

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0912520

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20101105